Categories AlphaGraphs, Consumer, Earnings
Earnings: Everything you need to know about Nike’s Q2 2023 results
Sportswear giant Nike, Inc. (NYSE: NKE) on Tuesday reported a modest increase in earnings for the second quarter of 2023, when its revenues grew in double digits. The latest numbers also came in above Wall Street’s expectations.
Second-quarter net income was $1.33 billion or $0.85 per share, compared to $1.33 billion or $0.83 per share in the corresponding period of fiscal 2022. The bottom line was negatively impacted by an increase in operating expenses.
November-quarter revenues grew 17% from last year to $13.3 billion. The top line also came in above the consensus forecast.
Check this space to read management/analysts’ comments on Nike’s Q2 2023 earnings
“Consumer demand for NIKE’s portfolio of brands continues to drive strong business momentum in a dynamic environment. We remain focused on what we can control, and we are on track to deliver on our operational and financial goals — setting the foundation for sustainable, profitable growth,” said Matthew Friend, chief financial officer of Nike.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training